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Thyroid autoimmunity, as reﬂected by the presence in serum
of autoantibodies directed against the thyroid autoantigens
thyroglobulin (Tg) and thyroid peroxidase (TPO), is present
in >10% of the US population over 12 years of age [1] and is
the most common cause of endocrine dysfunction in iodine-
suﬃcient populations [2]. The underlying mechanism is a
failure of T-cell tolerance leading to lymphocytic inﬁltration
of the thyroid gland [3] and to a complex sequence of
humoral and cellular immune responses to thyroid antigens,
presumably in response to an environmental trigger [4].
In chronic lymphocytic thyroiditis (CLT), the predomi-
nant immunologic mechanisms are T-cell- and cytokine-
mediated thyroid cell damage and apoptotic cell death
whereas in Graves’ disease (GD) generation of thyrotropin
(TSH) receptor autoantibodies leads to thyroid cell stimu-
lation [5], but signiﬁcant overlap exists. Seven susceptibility
genes, in addition to the major histocompatibility gene
(HLA-DR3), have now been identiﬁed [6]. Some of these
genesaﬀecttheimmuneresponseingeneral(CD40,CTLA-4,
and PTPN22), while others are thyroid speciﬁc (thyroglobu-
lin, thyrotropin (TSH) receptor). Some are common to both
CLT and GD, while others are speciﬁc for GD.
In view of the importance of AITD as well as the diverse
array of new information, it is only ﬁtting that this special
issue of the Journal of Thyroid Research is devoted entirely
to this complex subject. Four of the papers we have selected
are focused on clinical topics, including AITD in childhood,
during pregnancy, in the postpartum period, and in patients
with type 1 diabetes mellitus. The ﬁfth paper addresses the
potential role of NKT cells in an animal model of thyroiditis.
We conclude this special edition with a discussion of
thyroid autoimmunity in patients with papillary thyroid
cancer (PTC). The association of AI and thyroid cancer
was ﬁrst reported by Dailey et al. [7]. In general, patients
with AI appear more likely to have PTC than follicular
thyroidcancer(FTC),butalowerfrequencyofextrathyroidal
extension,nodalanddistantmetastaseswhencomparedwith
patients without AI. In some but not all series, patients
with autoimmune thyroiditis (AT) and PTC have improved
survival when compared to those with PTC alone, suggesting
that thyroid autoimmunity might contribute to improved
survival [8–10]. In contrast, other data suggest that AI might
actually increase the risk to develop thyroid cancer [10–
12].
Several theories have been proposed to explain how AI
might increase the risk for thyroid malignancy. Thyrocyte
apoptosis and proliferation are increased in AI suggesting
that thyrocytes rapidly progressing through the cell cycle
might accumulate increased DNA damage resulting in
malignant transformation [13]. Russell et al. hypothesized
that thyroid cells predestined to become cancers might
secrete proinﬂammatory cytokines that aﬀect immune cells
[14]. They showed that thyrocytes of ret/PTC3 transgenic
mice express increased levels of interleukins, tumor necrosis
factor-α,andcyclooxygenase-2[14]thatcouldattractand/or
activate cells of the immune system. Finally, the ret/PTC
recombinant genes have been detected in samples of AI [15–
17]suggestingthatret/PTCrearrangementsmightbepresent
in AI and could be precursors to PTC.
From these papers, it is clear that thyroid autoimmunity
is a frequent problem in the population and that thyroid
autoimmunity can lead to a variety of thyroid disorders
including alterations in thyroid hormone synthesis and
possibly even neoplasia. Focused research in this area is2 Journal of Thyroid Research
beginning to illuminate some of the molecular mechanisms
that help to explain these associations.
Rosalind Brown
Gary L. Francis
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